Celgene Corp., founded in 1986 and headquartered in Summit, New Jersey, is a biopharmaceutical company dedicated to developing innovative therapies for cancer and inflammatory disorders. The company's prominent products include Revlimid, a treatment for multiple myeloma, and Pomalyst, used for relapsed or refractory multiple myeloma, which have positioned Celgene as a leader in the biotechnology sector.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| CELG 3.45% 2027-11-15 USDCelgene Corp. | United States | 2027-11-15 | 3.450 | 4.06 |
| CELG 3.90% 2028-02-20 USDCelgene Corp. | United States | 2028-02-20 | 3.900 | 4.15 |
| CELG 4.35% 2047-11-15 USDCelgene Corp. | United States | 2047-11-15 | 4.350 | 6.57 |
| CELG 4.55% 2048-02-20 USDCelgene Corp. | United States | 2048-02-20 | 4.550 | 6.14 |
| CELG 4.63% 2044-05-15 USDCelgene Corp. | United States | 2044-05-15 | 4.625 | 6.85 |
| CELG 5.00% 2045-08-15 USDCelgene Corp. | United States | 2045-08-15 | 5.000 | 6.67 |
| CELG 5.25% 2043-08-15 USDCelgene Corp. | United States | 2043-08-15 | 5.250 | 6.75 |
| CELG 5.70% 2040-10-15 USDCelgene Corp. | United States | 2040-10-15 | 5.700 | 6.91 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Celgene first issued bonds in 2005, successfully entering the debt market to support its growth and research initiatives. Notable bond issuances include a $1 billion offering in 2014 that financed acquisitions and strengthened its financial position. As of 2023, Celgene's bonds yield approximately 4.5%, which is competitive relative to the industry average. The company’s Bonds have distinct features, such as call options and flexible maturities, enhancing appeal for investors. Following a merger with Bristol-Myers Squibb in 2019, the bond structure and performance have become an area of focus for retail investors tracking corporate transitions.